Agreement:
I Agree
Body:
Dear Editor
Professor Ageno et al have made an excellent contribution to the literature with their randomized controlled trial of 6 vs 12 weeks rivaroxiban for isolated distal DVT. What was striking was that ~50% of patients in both groups had no residual clot at the randomization visit. Could the authors report the post hoc subgroup analysis for the primary and secondary thrombotic outcomes stratified by presence or absence of residual clot on the 6 week ultrasound? Perhaps there is still a means of determining who will or won’t benefit from additional therapy.
No competing Interests:
Yes
The following competing Interests:
Electronic Publication Date:
Thursday, November 24, 2022 – 21:06
Highwire Comment Subject:
Workflow State:
Released
Full Title:
Does it matter if the clot had resolved?
Highwire Comment Response to:
Check this box if you would like your letter to appear anonymously::
Last Name:
Lee
First name and middle initial:
Todd C.
Email:
Address:
Royal Victoria Hospital, Montreal QC
Occupation:
Associate professor of medicine
Affiliation:
McGill University
BMJ: Additional Article Info:
Rapid response
Twitter:
@DrToddLee